Complement Regulation and Disease Associated with Deficiency

Core Idea

The complement cascade is tightly regulated by factor H, factor I, C1-inhibitor, and membrane-bound regulators (CD55, CD46) to prevent inadvertent self-damage. Deficiencies in early complement components (C1, C2, C4) increase autoimmune disease risk; deficiencies in alternative pathway components increase infection risk (especially Neisseria meningitidis). Dysregulation (e.g., factor H mutations in atypical HUS) causes complement-mediated tissue damage.

How It's Best Learned

Map complement regulatory molecules and their binding sites on pathogens. Study how pathogens exploit complement regulation to evade immunity.

Common Misconceptions

Complement deficiency does not uniformly impair immunity; early component deficiency may increase autoimmunity, while late component deficiency increases bacterial infection risk. Some pathogens hijack complement for cellular entry (e.g., Leishmania via CR1).

Explainer

From your study of complement activation pathways, you know that the complement cascade is a powerful system of sequentially activated proteases that can opsonize pathogens, recruit inflammatory cells, and directly lyse microbes through the membrane attack complex (MAC). But a system this destructive must be tightly controlled — without regulation, complement would damage the body's own cells just as readily as it attacks pathogens. The regulatory machinery exists at nearly every step of the cascade.

Fluid-phase regulators control complement activation in the blood. C1-inhibitor (C1-INH) is a serine protease inhibitor that inactivates C1r and C1s, shutting down the classical pathway at its earliest step. Deficiency of C1-INH causes hereditary angioedema, characterized by episodic, life-threatening swelling due to uncontrolled generation of vasoactive peptides. Factor H and Factor I work together to dismantle the alternative pathway C3 convertase: Factor H binds C3b on host cell surfaces (recognizing sialic acid markers of self) and serves as a cofactor for Factor I, which cleaves C3b into inactive iC3b. This is why host surfaces are protected while pathogen surfaces — lacking sialic acid — allow complement amplification to proceed.

Membrane-bound regulators provide cell-intrinsic protection. CD55 (decay-accelerating factor) accelerates the decay of C3 and C5 convertases on host cell surfaces, while CD46 (membrane cofactor protein) acts as a cofactor for Factor I-mediated cleavage of C3b. CD59 blocks the final assembly of the MAC by preventing C9 polymerization. Loss of CD55 and CD59 — as occurs in paroxysmal nocturnal hemoglobinuria (PNH), where a defect in GPI-anchor synthesis prevents these regulators from attaching to cell membranes — results in chronic complement-mediated destruction of red blood cells.

The clinical consequences of complement deficiency follow a logical pattern once you understand where each component acts. Deficiencies in early classical pathway components (C1q, C2, C4) are strongly associated with systemic lupus erythematosus and other autoimmune diseases — not because complement directly prevents autoimmunity, but because these components are essential for clearing immune complexes and apoptotic debris. When debris accumulates, it becomes a source of self-antigens that drive autoimmune responses. In contrast, deficiency of terminal components (C5–C9) specifically impairs MAC formation, leaving patients unable to lyse Gram-negative bacteria with thin cell walls — particularly Neisseria meningitidis and N. gonorrhoeae. Patients with terminal complement deficiencies may experience recurrent meningococcal infections. Mutations in Factor H illustrate the danger of dysregulation rather than deficiency: without Factor H to protect host surfaces, the alternative pathway attacks kidney endothelium, causing atypical hemolytic uremic syndrome (aHUS), a devastating condition characterized by thrombotic microangiopathy and renal failure.